Skip to main content
Figure 3 | Biomarker Research

Figure 3

From: Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

Figure 3

Overall survival of patients on present or discontinued treatment after 12 months. OS was measured from the date of initial nilotinib administration to the date of death, with a minimum follow-up of 24 months. OS was estimated using the Kaplan-Meier method and compared between groups using the stratified log-rank test. There was a significant difference between the 2 groups (log-rank test, P = 0.00844).

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us